| Bioactivity | SIMR3030 is a potent SARS-CoV-2 PLpro inhibitor with an IC50 value of 0.0399 µg/mL. SIMR3030 shows antiviral activity. SIMR3030 decreases SARS-CoV spike, ORF1b, IFN-α, IL-6 mRNA expression. SIMR3030 exhibits a satisfactory safety profile in mice[1]. |
| Target | IC50: 0.0399 µg/mL (SARS-CoV-2 PLpro) |
| Invitro | SIMR3030 (0-100 µg/mL) 显示抗病毒活性，对 SARS-CoV-2 和 MERS-CoV 的 IC50 值分别为 12.1、6.206 μg/mL[1]。SIMR3030 (20 µg/mL; 1, 6, 12 h) 降低 Caco-2 细胞中的 SARS-CoV spike、ORF1b、IFN-α、IL-6 mRNA 表达水平[1]。 RT-PCR[1] Cell Line: |
| In Vivo | SIMR3030 (25、50、100 mg/kg；I.p.；每日一次，持续 14 天) 在实验小鼠模型中表现出较好的安全性[1]。 Animal Model: |
| Name | SIMR3030 |
| CAS | 2708270-99-7 |
| Formula | C27H29N3O2 |
| Molar Mass | 427.54 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hersi F, et al. Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19. Eur J Med Chem. 2023 Jun 5;254:115380. |